OpGen, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own0.60% Shs Outstand46.48M Perf Week3.96%
Market Cap26.74M Forward P/E- EPS next Y-0.47 Insider Trans9.01% Shs Float46.28M Perf Month10.41%
Income-33.90M PEG- EPS next Q-0.15 Inst Own8.90% Short Float2.68% Perf Quarter-30.96%
Sales3.90M P/S6.86 EPS this Y31.00% Inst Trans-18.01% Short Ratio2.60 Perf Half Y-52.23%
Book/sh0.74 P/B0.72 EPS next Y6.60% ROA-50.90% Target Price2.12 Perf Year-77.91%
Cash/sh0.61 P/C0.87 EPS next 5Y- ROE-91.40% 52W Range0.31 - 3.72 Perf YTD-46.98%
Dividend- P/FCF- EPS past 5Y70.90% ROI-36.60% 52W High-85.75% Beta-0.49
Dividend %- Quick Ratio1.70 Sales past 5Y1.40% Gross Margin36.30% 52W Low71.03% ATR0.07
Employees99 Current Ratio1.80 Sales Q/Q-37.50% Oper. Margin- RSI (14)49.36 Volatility12.85% 14.32%
OptionableNo Debt/Eq0.65 EPS Q/Q70.90% Profit Margin- Rel Volume0.36 Prev Close0.56
ShortableYes LT Debt/Eq0.23 EarningsMay 12 AMC Payout- Avg Volume477.68K Price0.53
Recom2.00 SMA20-6.02% SMA503.82% SMA200-55.49% Volume170,858 Change-5.99%
Mar-01-19Initiated Alliance Global Partners Buy $2.30
Feb-07-18Reiterated H.C. Wainwright Buy $1 → $9
Jun-29-16Initiated Rodman & Renshaw Buy $2.50
Jun-27-22 11:22PM  
Jun-22-22 08:00AM  
Jun-09-22 07:30AM  
May-26-22 07:30AM  
May-12-22 05:35PM  
Apr-28-22 07:30AM  
Apr-25-22 07:30AM  
Apr-20-22 07:30AM  
Apr-06-22 07:30AM  
Apr-05-22 07:30AM  
Mar-29-22 07:25PM  
Mar-24-22 07:05PM  
Mar-15-22 07:30AM  
Feb-28-22 07:55PM  
Feb-10-22 04:30PM  
Jan-18-22 07:30AM  
Jan-10-22 07:30AM  
Dec-14-21 07:30AM  
Dec-08-21 04:30PM  
Nov-30-21 08:45AM  
Nov-11-21 04:05PM  
Nov-04-21 03:01PM  
Oct-28-21 07:30AM  
Oct-21-21 07:30AM  
Oct-18-21 04:30PM  
Oct-14-21 08:00AM  
Oct-05-21 05:17AM  
Oct-04-21 02:59PM  
Sep-30-21 07:30AM  
Sep-16-21 09:03AM  
Sep-15-21 07:30AM  
Aug-12-21 07:55PM  
Aug-04-21 04:30PM  
Aug-03-21 07:30AM  
Jul-07-21 04:30PM  
Jun-30-21 07:30AM  
Jun-28-21 07:30AM  
Jun-15-21 02:14PM  
Jun-09-21 04:30PM  
Jun-07-21 10:36AM  
May-13-21 12:11PM  
Apr-29-21 12:34PM  
Apr-19-21 07:30AM  
Apr-12-21 07:30AM  
Mar-26-21 03:28AM  
Mar-25-21 05:25PM  
Mar-24-21 10:04AM  
Mar-18-21 12:30PM  
Mar-11-21 07:30AM  
Mar-09-21 08:03AM  
Mar-08-21 07:30AM  
Mar-01-21 07:30AM  
Feb-22-21 09:47AM  
Feb-16-21 07:30AM  
Feb-09-21 08:30AM  
Jan-13-21 11:02AM  
Jan-11-21 10:11AM  
Jan-05-21 07:30AM  
Dec-17-20 08:00AM  
Dec-09-20 07:30AM  
Dec-01-20 07:30AM  
Nov-24-20 08:00AM  
Nov-12-20 07:30AM  
Nov-11-20 04:05PM  
Oct-29-20 07:30AM  
Oct-28-20 07:30AM  
Oct-26-20 09:51AM  
Oct-15-20 07:30AM  
Oct-14-20 07:53AM  
Oct-13-20 05:00PM  
Oct-12-20 10:19AM  
Oct-05-20 08:19AM  
Sep-30-20 07:30AM  
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILUM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bacher JohannesChief Operating OfficerMar 03Option Exercise0.0021,250081,250Mar 04 11:03 AM
Schacht OliverChief Executive OfficerMar 03Option Exercise0.0038,750068,750Mar 04 11:01 AM
Bacher JohannesChief Operating OfficerJan 26Buy0.8525,00021,25060,000Jan 27 06:19 AM
Bacher JohannesChief Operating OfficerNov 19Buy1.5310,00015,34735,000Nov 19 02:46 PM
Schacht OliverChief Executive OfficerNov 18Buy1.5010,00014,96030,000Nov 19 08:48 AM
Schacht OliverChief Executive OfficerSep 15Buy3.085,00015,40020,000Sep 15 04:21 PM
Bacher JohannesChief Operating OfficerSep 15Buy3.075,00015,35025,000Sep 16 06:03 AM